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Open access unBackground and purpose: Stereotactic ablative radiotherapy (SABR) has improved the survival for medi-
cally inoperable patients with peripheral early-stage non-small cell lung cancer (NSCLC). We performed
a systematic review of outcomes for central lung tumours.
Material and methods: The systematic review was performed following PRISMA guidelines. Survival out-
comes were evaluated for central early-stage NSCLC. Local control and toxicity outcomes were evaluated
for any centrally-located lung tumour.
Results: Twenty publications met the inclusion criteria, reporting outcomes for 563 central lung tumours,
including 315 patients with early-stage NSCLC. There was heterogeneity in the planning, prescribing and
delivery of SABR and the common toxicity criteria used to deﬁne toxicities (versions 2.0–4.0). Tumour
location (central versus peripheral) did not impact overall survival. Local control rates wereP85% when
the prescribed biologically equivalent tumour dose wasP100 Gy. Treatment-related mortality was 2.7%
overall, and 1.0% when the biologically equivalent normal tissue dose was 6210 Gy. Grade 3 or 4 toxic-
ities may be more common following SABR for central tumours, but occurred in less than 9% of patients.
Conclusions: Post-SABR survival for early-stage NSCLC is not affected by tumour location. SABR achieves
high local control with limited toxicity when appropriate fractionation schedules are used for central
tumours.
 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 106 (2013) 276–282Anatomic surgical resection is the treatment of choice for pa-
tients diagnosed with early-stage non-small cell lung cancer
(NSCLC) [1,2]. For tumours that are centrally located, more exten-
sive surgical procedures are required due to tumour invasion into
the major bronchi and/or vessels [3,4], which is associated with a
higher mortality and morbidity [5]. Thus, the treatment of central
tumours represents a high-risk clinical scenario in which the risks
associated with surgery have been deemed acceptable.
As the global population ages, the proportion of elderly lung
cancer patients and those with comorbidities will also increase
[6–9]. For the unﬁt elderly with peripheral early-stage NSCLC, ste-
reotactic ablative radiotherapy (SABR) is considered the preferred
treatment [2], offering improved survival and quality of life over
conventional radiotherapy [10,11]. In an early SABR trial, fractions
of 20–22 Gy, delivering total doses of 60–66 Gy to central tumours
were associated with a greater than 10-fold increased risk of high-
grade toxicity or death [12]. This led to an ongoing Radiation Ther-
apy Oncology Group (RTOG) phase I/II trial (0813) speciﬁcally for
central tumours, to determine the maximum tolerated dose whichadiation Oncology, VU Uni-
msterdam, The Netherlands.
der CC BY-NC-ND license.can be delivered in ﬁve fractions [13]. Similarly, it has lead others
to suggest that the risks associated with SABR for central tumours
may be prohibitive and high-dose accelerated radiotherapy be the
subject of further research [14].
As reports from Japanese and Dutch investigators have reported
favourable outcomes in early-stage tumours using daily fractions
of 6.0–7.5 Gy to total doses of 48–60 Gy [15,16], many centres have
continued to use SABR for central tumours. We performed a sys-
tematic review of published literature on the clinical outcomes of
SABR for central lung tumours.Methods
A systematic review was performed according to the PRISMA
guidelines [17]. We searched for English-language papers pub-
lished from January 2000 to August 2012. The inclusion criteria
were:
1. Studies reporting clinical outcomes following SABR for primary
NSCLC or metastatic lung tumours and,
2. Studies speciﬁcally reporting clinical outcomes for centrally
located tumours.
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1. They were review articles or case reports,
2. They were not the most recently published outcomes, in
instances of multiple publications from the same study cohort.
Using PubMed, the search was completed in August 2012. The
search strategy was (sabr[tw] OR sbrt[tw] OR srt[tw] OR stereotac-
tic[tw]) AND lung[tw] AND (central[tw] or centrally[tw]), which
identiﬁed 86 studies. Two clinicians reviewed these and the refer-
ence lists of selected articles to determine which were suitable for
inclusion. Survival outcomes were restricted to patients with cen-
tral early-stage NSCLC [18]. Local control and toxicity outcomes in-
cluded those reported for any central tumour receiving SABR.
Toxicity outcomes were included when graded using the Common
Toxicity Criteria (CTC) protocol version in place at the time. The
prescribed tumour doses were converted into a biologically equiv-
alent dose (BED) to enable comparison between studies, acknowl-
edging the limitations of this approach [19,20]. The BED was
calculated using the assumption that tumour and normal tissue al-
pha/beta ratios were 10 Gy (BED10) and 3 Gy (BED3), respectively
[21]. BED10 calculations were made using the dose delivered to
at least 95% of the planning target volume (PTV). BED3 calculations
were made using the prescribed dose schedules and the maximum
organ at risk doses received when studies provided this detail. BED
calculations did not take into account tumour doubling time or the
length of treatment.
Results
A total of 20 studies were found suitable for inclusion. Four of
these were prospective [22–25], including two Phase II studies
[23,24]. Seven studies reported clinical outcomes for NSCLC to-
gether with metastatic tumours [26–32] and one reported out-
comes restricted to central early-stage NSCLC alone [32]. From
these 20 studies, a total of 563 central tumours (including 315
early-stage NSCLC patients) received SABR. The radiotherapy de-
tails of these studies are summarized in Table 1. In these studies
toxicities were described using CTC versions 2.0, 3.0 and 4.0.Survival
The only prospective survival outcomes (n = 22) speciﬁc to cen-
tral early-stage NSCLC were reported by Fakiris et al. [24], updating
the initial report from Timmerman et al. [12]. The median overall
survival was 24 months (95% CI 18–42), which was not statistically
different (p = 0.697) from that of peripheral tumours. Haasbeek
et al. reporting outcomes from the largest retrospective cohort,
found the 3-year overall survival for central (n = 63) and peripheral
(n = 445) early-stage NSCLC was statistically no different, 64% vs.
51% (p = 0.09) respectively [32]. Bradley et al. reported a 2-year
overall survival of 75% for all early stage NSCLC and found central
(vs. peripheral) location did not impact survival on both univariate
(p = 0.429) and multivariate analyses [33]. Similarly, Janssen et al.
found fractionation schedule, which depended on tumour location
alone, did not impact survival on both univariate and multivariate
analyses [31], while Andratschke et al. found tumour location did
not impact survival on univariate analysis for histologically proven
early-stage NSCLC (p = 0.653) [34]. Cause-speciﬁc survivals for cen-
tral early-stage NSCLC have been reported to be greater than 80% at
2–3 years [30,33,35]. Table 2 details all reported survival outcomes.Local control
After a median follow-up of 16 months, a prospective trial by
Bral et al. found that tumour location did not impact recurrence,with the crude local control for central tumours being 94% (1/17)
[23]. Retrospective studies have reported similar local control out-
comes, with 2 and 3-year rates typically exceeding 85% [23,26,31–
33,36–38], as shown in Table 2. However, six studies have reported
poorer local control, of between 60–76% [27,29,30,34,35]. In two of
these, SABR was prescribed to the isocentre, leading to a signiﬁ-
cantly lower peripheral tumour doses being delivered [29,35]. In
the third study, 23% (12/53) of patients had stage II, III or recurrent
stage III disease and 10% (6/63) of lesions had SABR delivered as a
radiotherapy boost following conventional radiotherapy [27].
Although stage-speciﬁc local control outcomes were not reported,
in the latter study the 2-year survival for non-stage I patients was
12%. In the fourth study reporting poorer local control, only 64%
(37/58) of tumours had planning target volume coverage above
95% as under-dosage was permitted to meet normal organ con-
straints [30]. Additionally, in this study multiple fractionation
schedules were utilized, and local control was 85% when the
BED10 was P100 Gy and 60% when the BED10 was <100 Gy. In
the last two studies, the modal prescribed doses were 35 Gy [34]
and 40 Gy [27] in ﬁve fractions, resulting in a respective BED10 of
60 and 72 Gy.
The importance of maintaining a BED10 of at least 100 Gy to the
tumour periphery was evident from a number of studies. Using a
schedule of ﬁve fractions, Olsen et al. reported a 100% 2-year local
control using a total dose of 50 Gy (BED10 100 Gy) and 50% using
45 Gy (BED10 86 Gy) [38]. Here, fractionation schedule was the
only factor found to impact local control on multivariate analysis
(p = 0.019). Similarly, Rowe et al. reported a 2-year local control
of 94% with a BED10 P100 Gy and 80% when <100 Gy, (p = 0.02)
[37]. Using a SABR schedule of four fractions, Chang et al. reported
a crude local control of 100% with a total dose of 50 Gy (BED10 113)
vs. 57% using 40 Gy (BED10 80 Gy) [26]. Two additional studies in
which central and peripheral tumours were analysed together, also
found that a BED10 above 100 Gy improved local control [15,25].
The post-SABR regional and distant control rates speciﬁcally
for central early-stage NSCLC have been infrequently reported.
Haasbeek et al. reported 2-year regional and distant control rates
of 91% and 73%, respectively, which were no different from
peripheral tumours treated by the authors using SABR over the
same period, 86% (p = 0.47) and 75% (p = 0.72), respectively
[32]. Two additional studies reported a crude distant recurrence
rate of approximately 15%, which was the predominant pattern
of recurrence [26,36].Treatment-related mortality
In a prospective study utilizing a SABR fractionation with a BED3
of 460 Gy, Fakiris et al. reported 18% (4/22) of patients with central
tumours had potential treatment-related deaths [24]. Although an
independent committee deﬁned these, they included infective
pneumonia and haemoptysis in the setting of local recurrence. Bral
et al. reported the only other prospectively deﬁned treatment-re-
lated death, a case of fatal haemoptysis after stent insertion for
bronchial stricture [23]. Milano et al. reported 8.7% (4/46) mortal-
ity rate using SABR for central non-stage I NSCLC and no mortali-
ties treating central stage I tumours [27]. It must be noted that
in three (75%) of these cases, the authors could not exclude respi-
ratory infection as the cause of death. Onimura et al. and Unger
et al. each reported one treatment-related death, which were
caused by an oesophageal ulcer (BED3 154 Gy) and bronchial ﬁs-
tula (BED3 209 Gy) respectively [15,28]. The latter two cases are
the only cases of treatment-related death observed when the pre-
scribed BED3 was 6210 Gy.
Table 3 details all treatment-related mortality reported for cen-
trally located tumours. The overall treatment-related mortality
rate from central tumours receiving SABR was 2.8% (16/563). For
Table 1
Baseline radiotherapy details.
Author (year) Simulation Target volumes Image guidance Prescription Heterogeneity
correction
Total dose gray/
fractions
Onimura [15] (2003) Inspiration, expiration, standard
CT
ITV + PBM = PTV Orthogonal x-rays Isocentre, PTV got 80% No 48/8
Xia [22] (2006) Slow CT and ﬂuoroscopy GTV + 10 mm = PTV Not reported 50% Isodose covering 95% PTV No 50/10
Chang [26] (2008) 4-Dimentional CT ITV + 8 mm = CTV + 3 mm = PTV CT-on-rails and orthogonal X-ray 75–90% Isodose covering PTV Yes 50/4
Song [36] (2009) Standard CT with ﬂuoroscopy GTV + PBM = PTV Conebeam CT 85% Isodose covering 95% PTV No 48/4a
Milano [27] (2009) Expiratory breath hold CT GTV + PBM = PTV Stereoscopic X-ray Isocentre,PTV got 80% No 50/5a
Fakiris [24] (2009) Standard CT GTV = CTV + PBM = PTV No reported 80% Isodose covering 95% PTV No 60/3
Guckenberger [40]
(2009)
4-Dimentional CT ITV + 5 mm = PTV Conebeam CT 65% Isodose covering PTV Yes 48/8
Unger [28] (2010) Inhalation breath hold. ﬁducials GTV = PTV Respiratory tracking ﬁducial
markers
70–80% Isodose covering 95%
PTV
Yes 40/5
Oshiro [29] (2010) Expiratory breath hold CT GTV + PBM = PTV Gated X-ray Not reported, likely to isocentre No 50/5a
Baba [35] (2010) Inspiration, expiration, standard
CT
ITV + PBM = PTV Not reported Isocentre, 95% of PTV got 80% Yes 50/4
Bradley [33] (2010) 4-Dimentional CT ITV + PBM = PTV Not reported 75–85% Isodose covering 95%
PTV
Yesb 45/5
Andratschke [34] (2011) Multiple standard and slow CT ITV + PBM = PTV Orthogonal x-rays 60% Isodose covering 100% PTV Yes 35/5a
Haasbeek [32] (2011) 4-Dimentional CT ITV + 3 mm = PTV Orthogonal X-ray 80% Isodose covering 99% PTV No 60/8
Bral [23] (2011) Planning PET CT and ﬂuoroscopy ITV + 5 mm = PTV Stereoscopic X-ray 95% Isodose covering 95% PTV No 60/4
Olsen [38] (2011) 4-Dimentional CT ITV + PBM = PTV Conebeam CT 60–90% Isodose covering 95%
PTV
Yes 50/5a
Stauder [39] (2011) 4-Dimentional CT ITV + PBM = PTV Conebeam CT 100% Isodose covering 95% PTV Yesb 48/4
Rowe [37] (2012) 4-Dimentional CT ITV + 7 mm = PTV Conebeam CT 100% Isodose covering 95% PTV Yes 50/4a
Nuyttens [30] (2012) Standard CT GTV + 5 mm = PTV Respiratory tracking ﬁducial
markers
75–90% Isodose covering 95%
PTV
Yes 60/5a
Taremi [25] (2012) 4-Dimentional CT ITV + 5 mm = PTV Conebeam CT 100% Covered 95% of PTV Yesb 60/8
Janssen [31] (2012) 4-Dimentional CT ITV + 3 mm = CTV + PBM = PTV Conebeam CT 80% Isodose covering PTV No 48/8
Population based margins (PBM) utilized to account for tumour motion were typically 5 mm radially and 8–10 mm longitudinally.
a Modal dose fractionation schedule shown when multiple schedules were utilized.
b Heterogeneity correction not utilized in all treatments.
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Table 2
Survival and local control.
Author (year) BED10 Overall survival Cause-speciﬁc survival Local control
Chang [26] (2008) 113 – Crude rate 89%
Song [36] (2009) 106 50% at 2 years – 89% at 2 years
Milano [27] (2009) 100 72% at 2 years – 73% at 2 years
Fakiris [24] (2009) 180 Median 24 months – –
Unger [28] (2010) 72 – – 63% at 1 year
Oshiro [29] (2010) 80 – – 60% at 2 years
Baba [35] (2010) 90 72% at 3 years 82% at 3 years 66% at 3 years
Bradley [32] (2010) 86 75% at 2 yearsa,b 90% at 2 yearsa,b 86% at 2 years
Andratschke [34] (2011) 60 29% at 3 years – 64% at 3 years
Haasbeek [32] (2011) 105 64% at 3 years – 93% at 3 years
Bral [23] (2011) 150 – – Crude rate 94%
Olsen [38] (2011) 100 – – 100% at 2 years c
Rowe [37] (2012) 114 – – 94% at 2 years
Nuyttens [30] (2012) 132 53% at 3 yearsb 3 years 80% 76% at 2 years
Janssen [31] (2012) 77 – – 87% at 1 yeara
Biologically equivalent tumour dose (BED10). Survival outcomes for central early-stage NSCLC. Local control for all central lung tumours receiving SABR.
a Includes central and peripheral tumours with multivariate analysis showing location had no impact on outcome.
b Outcome not reported speciﬁcally but estimated from Kaplan–Meier curve.
c Local control at 2-years using 45 and 50 Gy in ﬁve fractions was 50% and 100%, respectively (p = 0.006).
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death was 3.6% (13/359), while it was 1.0% (2/204) when the SABR
schedule had a BED3 <210 Gy.
The median duration of follow-up in all 20 studies was
19 months (range 10–50). Of the studies reporting treatment-re-
lated death, the median time to death following SABR was
7.5 months (range 5–12.5) [15,24,27,37,39].Grade 3 or 4 toxicity
Bral et al. reported a 2-year grade 3 or higher lung toxicity free
survival of 60% for central tumours in a prospective trial, with a
trend towards statistical signiﬁcance compared to peripheral le-
sions (80%, p = 0.06) [23]. Baba et al. observed a similar trend of
higher pulmonary toxicity treating central tumours, with the rate
of grade 2–3 pneumonitis being 25% vs. 11% for peripheral tumours
(p = 0.11) [35]. A detailed description of all grade 3 or 4 toxicities,
and the CTC protocol version used to deﬁne them are shown in Ta-
ble 3. Amongst the toxicities observed, respiratory toxicity includ-
ing pneumonitis, pneumonia, dyspnoea (typically increased
oxygen requirement in patients already using oxygen) and bron-
chial stricture were the most prevalent. There was one reported
case of grade 3 esophagitis, rib fracture and pericarditis each
[27,32,40].
Using a wide range of fractionation schemes, Song et al. re-
ported that 33% (3/9) of patients with central tumours developed
high-grade bronchial stricture post-SABR and that 89% (8/9) devel-
oped any stricture [36]. Patients who developed high-grade stric-
tures in their report were prescribed 40–48 Gy delivered in four
fractions (BED3 173–240 Gy). Bral et al. and Nuyttens et al. ob-
served high-grade toxicity in 23.5% (4/17) and 17.2% (10/58),
respectively [23,30]. These studies utilized SABR fractionation
schemes with a BED3 of 360 Gy and 300 Gy (modal). However, all
ten high-grade toxicities seen by Nuyttens et al. were grade 3
pneumonitis, with the authors reporting that seven of these had
probable co-existing infections. Three studies, treating 47 central
tumours, reported no grade 3 or 4 toxicity when using a BED3 rang-
ing between 133–144 Gy [15,22,31].
After excluding studies in which toxicity outcomes for both cen-
tral and peripheral tumours or grade 2 and 3 toxicity were not re-
ported separately, grade 3 or 4 toxicity occurred in 8.6% (36/418) of
central tumours treated with SABR.Discussion
Although surgery offers the best chance of survival for early-
stage NSCLC, patients with a clinical diagnosis of stage I NSCLC
have a 5-year survival of only 43–50% [1,2]. Surgery is less likely
to be recommended for the elderly and those with comorbidities
[9,41]. For these patients, increasing access to SABR has improved
population-based survival [41–44]. Due to concerns about the
safety of SABR for central tumours, we performed a systematic re-
view, which identiﬁed 20 studies reporting clinical outcomes for
563 central tumours receiving SABR. Our main ﬁndings were that
the overall survival reported following SABR for both central and
peripheral early-stage NSCLC was similar, and the risk of high-
grade toxicity post-SABR for central lung tumours was less than
9%. Moreover, when utilizing appropriate fractionation schedules
in which the BED10 P100 Gy and BED3 6210 Gy, local control ex-
ceeded 85% and the risk of treatment-related mortality was less
than 1%.
Although pneumonectomy was traditionally performed for cen-
tral lung tumours, the use of broncho-angioplastic procedures has
reduced pneumonectomy rates for stage I NSCLC to between 5%
and 11% [45–47]. However, irrespective of the type of surgery per-
formed for central stage I NSCLC, perioperative mortality and sur-
gical complication rates are approximately 4.5% and 25%,
respectively, as shown in Table 4 [5]. In addition, patients undergo-
ing broncho-angioplasty have an 8% risk of stump/anastamotic
complication, which includes bronchial necrosis, dehiscence, stric-
ture and ﬁstula formation [5]. These ﬁndings indicate that the risk
of mortality and morbidity in treating central tumours can be con-
siderable, even when patients are ﬁt enough to undergo surgery.
Despite this, surgery is still recommended whenever possible for
early stage NSCLC [1,2]. A randomized trial comparing sublobar
resection, with or without brachytherapy, for high-risk operable
patients reported 33% of patients in either trial arm had grade 3
or worse toxicity [48]. This suggests that our ﬁndings of a 9% risk
of high-grade toxicity, and less than 1% risk of treatment-related
mortality following SABR for central tumours in elderly patients
with comorbidities, should not preclude the continued evaluation
of SABR in this patient group.
Despite the potential inaccuracies inherent to the linear-
quadratic model to estimate the biologic tumour and normal tissue
effects with SABR fractionation schedules [19,20], multiple studies
have found a correlation between clinical outcomes and the BED
Table 3
Treatment-related mortality and severe toxicity.
Author (year
published)
Follow-
up
(months)
Central
tumours
(n)
Central
early-stage
NSCLC (n)
Central tumours
eligible for RTOG
0813
BED3
(Gy)
GTV size
(range)e
Grade 5 toxicity (clinical details if provided) Grade 3–4 toxicity (clinical details if provided) Grading
system
Onimura [15]
(2003)
18 9a,b Not speciﬁed Nof 144 Max < 60 mm 1  Oesophageal ulcer (5 months. Max dose BED3 154 Gy) None –
Xia [22]
(2006)
27 9 9 Unclear 133 Max < 100 mm None None –
Chang [26]
(2008)
17 27 13c Nof 258 Max < 40 mm None * –
Song [34]
(2009)
27 9 9 Yes 240 d Median
23 mm (12–
45)
1  Bronchial stricture (max dose 48 BED3 240 Gy) 2  Bronchial stricture (Max dose 40/4 both, BED3
173 Gy)
CTC (v2)
Milano [27]
(2009)
10 63a 7 Yes 217d Median 10 cc
(0.5–277)
1  Haemoptysis, 3  dyspnoea (at median 6.3 months. All
patients with stage II-III NSCLC and received multiple
courses of SABR)
1  Pneumonia, 1  pericarditis CTC (v3)
Fakiris [24]
(2009)
50 22 22 Yes 460 Max < 70 mm 3  Pneumonia, 1  haemoptysis, 1  dyspnoea (median
12.5 months, 4 in central tumours)
1  Apnoea, 1  pneumonia, 2  pleural effusion,
1  anxiety (At median 7.6 months, 2 in central tumours)
CTC (v2)
Guckenberger
[40] (2009)
14 22 6 Unclear 144 Max < 256 cc None * –
Unger [28]
(2010)
10 20 3 Yes 147 Median 73 cc
(23–324)
1  Bronchial ﬁstula (max dose 49 Gy BED3 209 Gy) 1  pneumonitis CTC (v3)
Oshiro [29]
(2010)
20 21 1 Yes 217d Median
28 mm (10–
40)
1  Haemoptysis (second course BED3 230 Gy) 1  Bronchial stricture (BED3 180 Gy), 1  dyspnoea
(BED3 217 Gy)
CTC (v3)
Baba [35]
(2010)
26 29 29 Unclear 258 Max < 55 mm None * –
Bradley [33]
(2010)
18 8 8 Nof 180 Max < 51 mm None * –
Andratschke
[34] (2011)
21 24 24 Yes 117 Max < 203 cc None * –
Haasbeek [32]
(2011)
35 63 63c Nof 210 Median
36 mm (15–
74)
None Acute 1  chest wall pain. Late 2  dyspnoea, 1  rib
fracture, 1  chest wall pain (occurred in 5 patients)
CTC (v3)
Bral [23]
(2011)
16 17 17 Yes 360 Max < 60 mm 1  Bronchial stenosis/haemoptysis Acute 2  pneumonitis, 2  cough, 1  pneumonia. Late
3  pneumonitis, 1  pneumonia (occurred in 4 patients)
CTC (v3)
Olsen [38]
(2011)
11 15 15c Nof 217 Not speciﬁed None * –
Stauder [39]
(2011)
16 47a,b Not speciﬁed Yes 240 Max < 60 mm 1  Bronchial stricture (7.5 months) 1  dyspnoea CTC (v3)
Rowe [37]
(2012)
11 51a,c 30 Nof 258d Median
31 mm (11–
57)
1  Haemoptysis (10.5 months. Max dose 54 Gy BED3
297 Gy)
3  Dyspnoea, 1  pneumonitis CTC (v4)
Nuyttens [30]
(2012)
23 58a 39 Nof 300d Median
41 mm (12–
105)
None Acute 4  pneumonitis. Late 6  pneumonitis. (3 were
clearly SABR-related, 7 were more likely felt to be COPD
exacerbation).
CTC (v3)
Taremi [25]
(2012)
19 20 20 Unclear 210 Max < 57 mm None * -
Janssen [31]
(2012)
14 29b Not speciﬁed Unclear 144 Max < 142 cc None None -
Biologically equivalent normal tissue dose (BED3).
a Study outcomes reported with respect to number of central tumours not patients.
b Study did not specify number of early-stage non-small cell lung cancer patients although these were included in the study cohort.
c Includes early-stage cases with tumours in the lung apex or adjacent to other non-hilar central structures.
d Modal BED3 shown if multiple fractionation schedules were utilized.
* Grade 3–4 toxicity speciﬁc to central tumours was not reported separately (includes reports in which central and peripheral or grade 2 and 3 outcomes were reported together). These studies were therefore excluded when
calculating the overall rate of grade 3 or 4 toxicity.
e Max gross tumour volume (GTV) of all tumours treated is shown when central tumour sizes are unavailable.
f Include tumours within 2 cm of the mediastinum or brachial plexus, rather than only those in direct contact with the mediastinal or pericardial pleura as speciﬁed in radiation therapy oncology group (RTOG) 0813.
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Table 4
Clinical outcomes of stage I lung cancer by surgical technique.
Surgical technique Patients
(n)
5-year Survival
(%)
Loco-regional recurrence
(%)
Any recurrence
(%)
30-day
mortalitya(%)
Operative
complicationsa(%)
Bronchoplasty [5] 355 61.0 10.0 17.5–22.5 4.4 23.6
Bronchoplasty and angioplasty
[4]
39 48.0 5.1 33.0 3.3 32.4
Pneumonectomy [5] 224 49.0 19.7 40.9 4.8 26.2
a Outcomes not restricted to stage I tumours.
S. Senthi et al. / Radiotherapy and Oncology 106 (2013) 276–282 281[40,49–52]. Onishi et al. describing a cohort of 245 patients from
multiple Japanese institutions, found using a BED10 P100 Gy sig-
niﬁcantly improved both local control (92% vs. 74%, p < 0.05), and
3-year overall survival (88% vs. 69%, p < 0.05) [50]. In addition, local
control was not improved further when patients received a BED10
P120 orP140 Gy. More recently, an analysis of a cohort of 505 pa-
tients treated across ﬁve counties found that a BED10P105 Gy was
associated with higher local control, 96% vs. 85% (p < 0.001) [52].
Our analysis found that central tumours had the same dose–re-
sponse relationship for local control, with four studies reporting
improved outcomes with a BED10 P100 Gy compared to lower
doses [26,30,37,38]. Interestingly, we observed a similar dose–re-
sponse relationship for treatment-related mortality, with a BED3
6210 Gy reducing the risk of death by approximately 75%.
Multiple fractionation schedules may or may closely achieve a
BED10 P100 Gy and BED3 6210 Gy. These include schedules of:
50 Gy in 5 fractions, 54 Gy in 6 fractions, 56 Gy in 7 fractions and
60 Gy in 8 fractions. 50 Gy in 5 fractions was the modal fraction-
ation schedule used in three studies [27,29,38]. Of these, Milano
et al. reported the only treatment-related deaths (n = 2) when uti-
lizing 50 Gy in 5 fractions, both of which occurred in patients
receiving SABR for node-positive NSCLC [27]. In two studies, 83
central early-stage NSCLC patients were treated using 60 Gy in 8
fractions and none died as a result of their treatment [25,32]. As
the aforementioned studies ensured the PTV received at least
95% of the prescribed dose without deliberate under-dosing to re-
duce organ at risk toxicity, it is likely that these schedules enable
the safe treatment of central lung tumours. Of the 20 studies in-
cluded in this review, deliberate under-dosing of the PTV was de-
scribed in only one study which may, in part, have accounted for
a lower local control rate of 76% at 2 years [30].
A number of limitations in this analysis must be recognized.
Follow-up amongst the included publications was generally lim-
ited, with the median being 19 months (range 10–50). However,
this may be sufﬁciently long as a study of post-SABR patterns of
recurrence in 676 patients with early-stage NSCLC found the med-
ian times to local, regional and distant recurrences were 14.9, 13.1
and 9.6 months, respectively [53]. There was signiﬁcant heteroge-
neity within the included studies with respect to the planning, pre-
scribing and delivery of SABR (Table 1). We found variations in the
way SABR doses were prescribed [29,35] and how normal organs
were contoured [15] which may have impacted local control and
toxicity, respectively. In addition, there was heterogeneity in the
deﬁnition of ‘central’, with little additional details on location to
enable assessment of the toxicity risk for given clinical scenarios.
The majority of the publications in this review did not use 4-
dimentional CT based planning, instead used techniques which
could have led to larger target volumes and an increased risk of
toxicity [54,55]. When considering the treatment of central tu-
mours, careful contouring of organs at risk [56] and strict quality
assurance of all aspects of treatment planning and delivery are re-
quired [57,58]. Additionally, current treatments must account for
the fact that dose calculation algorithms in use today are more
accurate than those used historically, even if the impact of this
may be less with central lung tumours [59,60].In summary, this systemic review suggests SABR offers a safe
and effective curative treatment for patients with central tumours
who unﬁt for surgery. Data from the ongoing RTOG 0813 trial will
provide prospective data to determine more reliable normal organ
constraints with respect to the SABR fractionation schedules being
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